We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck’s fourth quarter earnings plummeted by more than 20 percent as a result of its September 2004 recall of the pain reliever Vioxx
Merck said its fourth quarter profits fell from $1.4 billion, or 62 cents a share, in the fourth quarter of fiscal 2003 to $1.1 billion, or 50 cents a share, in the fourth quarter of fiscal 2004 — a 21 percent decline in profit.
According to new data recently released by the Centers for Medicare & Medicaid Services (CMS) spending growth for prescription drugs in the U.S. decelerated at a rapid rate in 2003.
The country’s first state-sponsored prescription drug importation program has seen only a handful of participants, although millions of residents are eligible for the program.
The agreement between the FDA and the Centers from Medicare & Medicaid Services (CMS) to conduct parallel reviews of products — which would allow drugmakers to receive both a drug approval and reimbursement coverage simultaneously — could speed some products to market, but it also raises concerns for the pharmaceutical industry, according to experts.
California lawmakers will consider legislation requiring drugmakers to turn over all clinical trial data on every drug product sold in the state — one of several Rx-related bills that the state legislature is scheduled to address this session.
The Centers for Medicare & Medicaid Services (CMS) plans to issue a guidance in March summarizing its policies on implementing an evidence-based approach to medicine — in which treatments are compared and selected based on effectiveness and value.
Maryland has laid plans to join a multistate prescription drug buying agreement that would let the states combine their Medicaid purchasing power to seek deeper discounts from drugmakers.
Ten large pharmaceutical firms have launched a discount card program that could help millions of uninsured Americans save about 25 to 40 percent on commonly used prescription drugs.
An evidence-based approach to medicine — in which treatments are compared and selected based on effectiveness and value — can lower costs and improve healthcare services, according to HHS officials and a consumer group.
A coalition of 10 large pharmaceutical firms has launched a discount card program that could help millions of uninsured Americans save about 25 to 40 percent on commonly used prescription drugs.